Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 21;14(10):2532.
doi: 10.3390/cancers14102532.

Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients

Madeline Devaux  1 , Mathieu Boulin  2 , Morgane Mounier  3   4 , Denis Caillot  5 , Nuri Ahwij  6 , Adélie Herbin  6 , Jean Noël Bastie  6 , Camille Favennec  6 , Philippine Robert  6 , Pauline Pistre  1 , Stephanie Bost  1 , Pauline Amiot  6 , Laurence Jacquesson  6 , Olivier Casasnovas  5 , Cédric Rossi  7 , Pauline Gueneau  1
Affiliations

Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients

Madeline Devaux et al. Cancers (Basel). .

Abstract

Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating a first highly haematotoxic treatment for Hodgkin or non-Hodgkin lymphoma. Patient follow-up is based on consultation with a pharmacist and planed phone calls by nurses supervised by a clinical haematologist. Our objective was to assess effectiveness and cost of the UMACOACH Lymphoma Program (ULP) and to investigate patient satisfaction and quality of life (QoL). Methods: This French monocentric case-control study included all patients enrolled in the ULP over a one-year period (cases) matched with retrospective patients receiving usual care (controls). Numbers of adverse events (AEs), re-hospitalisations, average relative dose intensity (ARDI), treatment response and survival were compared between the two groups. Among cases, patient satisfaction and QoL using the EORTC-QLQC30 questionnaire before and after treatment were evaluated. Results: Seventy-eight cases were matched to 78 controls. Twenty-six percent grade 3−4 AEs were observed in cases versus 38% in controls (p = 0.001). There were 76 and 88 re-hospitalisations in the case and control groups, respectively (p = 0.217). ARDI > 85% was observed in 92% and 82% of cases and controls, respectively (p = 0.138). No differences were observed in terms of treatment responses and survival. Estimated cost savings were of EUR 81,782 in favour of the case group. An improvement of 5.1 points was observed in the total QoL score before and after treatment in cases. Conclusions: A nurse−pharmacist−haematologist collaboration seems to be promising to reduce grade 3−4 AEs in HL and NHL patients receiving highly haematotoxic chemotherapy regimens. Cost savings from hospitalisation being avoided were also shown.

Keywords: follow-up; haematotoxicity; immunochemotherapy; lymphoma; nurse; pharmacist; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagram of the care pathway of the patient participating in the UMACOACH Lymphoma Program.
Figure 2
Figure 2
Description of UMACOACH Lymphoma Program. * QoL: Quality of Life; ULP: UMACOACH Lymphoma Program.
Figure 3
Figure 3
Flowchart.
Figure 4
Figure 4
Overall survival of cases (including in ULP) and control groups.
Figure 5
Figure 5
Progression-free survival of cases (including in ULP) and control groups.
See this image and copyright information in PMC

References

    1. Laurent C., Baron M., Amara N., Haioun C., Dandoit M., Maynadié M., Parrens M., Vergier B., Copie-Bergman C., Fabiani B., et al. Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. J. Clin. Oncol. 2017;35:2008–2017. doi: 10.1200/JCO.2016.71.2083. - DOI - PubMed
    1. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. Rossi C., Bastie J.N. Actualités thérapeutiques dans les lymphomes non hodgkiniens et le lymphome de Hodgkin. Rev. Méd. Interne. 2019;40:246–254. doi: 10.1016/j.revmed.2018.04.015. - DOI - PubMed
    1. Le Gouill S., Thieblemont C., Oberic L., Moreau A., Bouabdallah K., Dartigeas C., Damaj G., Gastinne T., Ribrag V., Feugier P., et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N. Engl. J. Med. 2017;377:1250–1260. doi: 10.1056/NEJMoa1701769. - DOI - PubMed
    1. Fitoussi O., Belhadj K., Mounier N., Parrens M., Tilly H., Salles G., Feugier P., Ferme C., Ysebaert L., Gabarre J., et al. Survival Impact of Rituximab Combined with ACVBP and Upfront Consolidation Autotransplantation in High-Risk Diffuse Large B-cell Lymphoma for GELA. Haematologica. 2011;96:1136–1143. doi: 10.3324/haematol.2010.038109. - DOI - PMC - PubMed

LinkOut - more resources